Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price objective hoisted by Morgan Stanley from $16.00 to $17.00 in a report released on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.
NRIX has been the topic of a number of other reports. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. HC Wainwright upped their price target on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Stephens reaffirmed an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, Royal Bank of Canada lifted their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $31.12.
View Our Latest Report on NRIX
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Research analysts predict that Nurix Therapeutics will post -2.92 earnings per share for the current year.
Insider Activity at Nurix Therapeutics
In other news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.20% of the company’s stock.
Hedge Funds Weigh In On Nurix Therapeutics
A number of hedge funds have recently added to or reduced their stakes in NRIX. Squarepoint Ops LLC bought a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at about $601,000. AQR Capital Management LLC increased its position in Nurix Therapeutics by 76.8% in the second quarter. AQR Capital Management LLC now owns 21,296 shares of the company’s stock worth $444,000 after buying an additional 9,254 shares during the period. Millennium Management LLC boosted its holdings in shares of Nurix Therapeutics by 60.2% during the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after acquiring an additional 225,374 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Nurix Therapeutics by 25.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock worth $479,000 after acquiring an additional 4,583 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Nurix Therapeutics in the 3rd quarter worth about $3,152,000.
About Nurix Therapeutics
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Recommended Stories
- Five stocks we like better than Nurix Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- How to Invest in Small Cap Stocks
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- These Are the Dividend Stocks Insiders Bought in January
- The Role Economic Reports Play in a Successful Investment Strategy
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.